Travere Therapeutics, Inc.
TVTX
Positions held
Your positionsTVTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Travere Therapeutics is well-positioned in the biotechnology industry with a strong focus on innovative therapies, which can lead to significant market opportunities as they address unmet medical needs.
- Revenue increased by 33% compared to the prior quarter, reaching $170 million.
- Gross margin improved to 94.6%, up from 79% in the previous quarter.
- The company's financial health is concerning, with a high debt-to-equity ratio of 2515.721, indicating significant leverage.
- Operating margin remains low, with a negative trend of -12.8% for the year 2025.
- The overall score indicates a 'Strong Sell' signal with a score of -16.00, reflecting bearish market sentiment.
Fundamentals
| Market cap | $4.91B | Enterprise value | $5.03B | Trailing P/E | — | Forward P/E | 9.23 |
| PEG | — | Price / book | 200.15 | Beta | 1.14 | Dividend yield | 0.00% |
| Revenue growth | 48.2% | Earnings growth | — | Gross margin | 59.2% | Operating margin | 2.3% |
| Profit margin | -7.3% | ROE | -2.4% | ROA | -3.7% | Debt / equity | 25.16 |
| Current ratio | 4.05 | Free cash flow | -$18.25M | Analyst recommendation | strong_buy | Mean target | $75.21 |
| 52w high | $68.73 | 52w low | $22.59 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $170M | $127M | $130M | $165M | $114M | — |
| Op margin | 2.3% | -29.0% | -25.0% | 15.1% | -11.1% | — |
| Net income | -$34.8M | -$37.1M | $2.7M | $25.7M | -$12.8M | — |
| Gross margin | 94.6% | 79.0% | 98.0% | 99.0% | 86.8% | — |
| Gross profit | $160M | $100M | $127M | $163M | $99.3M | — |
| Operating income | $4.0M | -$36.9M | -$32.4M | $24.9M | -$12.7M | — |
- Revenue +33% vs prior quarter ($170M vs $127M).
- Gross margin 94.6% (was 79% prior quarter).
- Operating margin expanded to 2.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $491M | $233M | $145M | $109M | — |
| Op margin | -12.8% | -137.8% | -259.4% | -292.2% | — |
| Net income | -$25.5M | -$322M | -$111M | -$278M | — |
| Gross margin | 97.9% | 96.7% | 92.1% | 96.0% | — |
| Gross profit | $480M | $225M | $134M | $105M | — |
| Operating income | -$62.8M | -$321M | -$377M | -$320M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Travere Therapeutics (TVTX) Is Down 6.7% After New FILSPARI Data And Patent Extension - What's Changed
2026-09-23 · Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI
2026-09-23 · Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
2026-09-22 · Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
2026-09-21 · Travere Therapeutics President and CEO Eric Dube Plans to Step Down
2026-09-21 · Travere Therapeutics Announces Planned Chief Executive Officer Transition
2026-09-18 · Travere Therapeutics Insider Sold Shares Worth $2,785,021, According to a Recent SEC Filing
2026-09-18 · Travere Therapeutics Insider Sold Shares Worth $2,337,695, According to a Recent SEC Filing
2026-09-18 · Travere Therapeutics Insider Sold Shares Worth $25,390,729, According to a Recent SEC Filing
2026-09-18 · Travere Therapeutics Insider Sold Shares Worth $13,135,397, According to a Recent SEC Filing
Price (daily)
Full chart · RSI · MACD · patterns